COPD Is Not a Fixed Fate

2026-10-20

COPD is not destiny. The message attached to the European Respiratory Society Congress deserves attention because it challenges therapeutic resignation without promising that damaged lungs can simply repair themselves. Chronic obstructive pulmonary disease remains incurable, but its symptoms, exacerbation risk and, in some circumstances, progression can be changed through treatment and prevention.

Modification demands better definitions. Smoking cessation can slow accelerated lung function decline, while long-acting bronchodilators reduce airway smooth muscle contraction and improve airflow. These are different achievements, and treating them as interchangeable obscures what patients actually gain. Exacerbations deserve particular attention because these episodes can trigger hospitalization and are associated with poorer survival. Inhaled corticosteroids can reduce exacerbations in selected patients, with blood eosinophil counts helping guide treatment decisions, but pneumonia risk must enter the calculation. Treatment is not reversal. Nor should an improvement in breathlessness automatically be presented as proof that the underlying disease has stopped progressing.

The neglected opportunity is delivery. Pulmonary rehabilitation improves exercise capacity and quality of life through structured exercise and education, yet access remains uneven. Vaccination, reduced exposure to smoke and pollutants, and checks on inhaler technique belong beside prescriptions rather than beneath them. Precision also requires restraint: a therapy that benefits one inflammatory phenotype may offer less benefit to another, and biological plausibility cannot substitute for clinical outcomes. Conference claims therefore deserve scrutiny for their patient populations, endpoints and duration of follow-up. Hope needs measurable consequences. The boundary is not between a damaged lung and a healthy one, but between damage accepted and suffering still preventable.

Recommendations